We are proud to inform you about the SAKK trial presented during the ASCO Annual Meeting 2020, May 29 - 31.

The abstract listed below has been accepted for Poster discussion:

• Sacha Rothschild et al.: SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

Further information about this poster discussion: 
https://meetinglibrary.asco.org/record/184538/abstract.